524636 Stock Overview
Oxygenta Pharmaceutical Limited manufactures and sells drugs and active pharmaceutical ingredients in India.
Oxygenta Pharmaceutical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹25.85|
|52 Week High||₹37.00|
|52 Week Low||₹9.12|
|1 Month Change||1.37%|
|3 Month Change||7.71%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||106.80%|
|Change since IPO||1,130.95%|
Recent News & Updates
|524636||IN Pharmaceuticals||IN Market|
Return vs Industry: Insufficient data to determine how 524636 performed against the Indian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 524636 performed against the Indian Market.
|524636 Average Weekly Movement||7.8%|
|Pharmaceuticals Industry Average Movement||6.3%|
|Market Average Movement||6.8%|
|10% most volatile stocks in IN Market||9.8%|
|10% least volatile stocks in IN Market||4.4%|
Stable Share Price: 524636 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 524636's weekly volatility (8%) has been stable over the past year.
About the Company
Oxygenta Pharmaceutical Limited manufactures and sells drugs and active pharmaceutical ingredients in India. Its products are used in anti-hypertensive, anti-ulcer, anti-cancer, anti-retroviral, and anti-viral therapies, as well as losartan potassium and gabapentin intermediates. The company was formerly known as S.S.
Oxygenta Pharmaceutical Fundamentals Summary
|524636 fundamental statistics|
Is 524636 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|524636 income statement (TTM)|
|Cost of Revenue||₹566.81m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.43|
|Net Profit Margin||-1.01%|
How did 524636 perform over the long term?See historical performance and comparison
Is 524636 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 524636?
Other financial metrics that can be useful for relative valuation.
|What is 524636's n/a Ratio?|
Price to Sales Ratio vs Peers
How does 524636's PS Ratio compare to its peers?
|524636 PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
524752 Decipher Labs
530665 Zenith Healthcare
543500 Evoq Remedies
530317 Godavari Drugs
524636 Oxygenta Pharmaceutical
Price-To-Sales vs Peers: 524636 is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (0.8x).
Price to Earnings Ratio vs Industry
How does 524636's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
Price-To-Sales vs Industry: 524636 is good value based on its Price-To-Sales Ratio (0.6x) compared to the Indian Pharmaceuticals industry average (1.6x)
Price to Sales Ratio vs Fair Ratio
What is 524636's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||0.6x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 524636's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 524636 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 524636's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 524636's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 524636's PEG Ratio to determine if it is good value.
Discover undervalued companies
- Take a look at our analysis of 524636's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Oxygenta Pharmaceutical regulatory filings.
How is Oxygenta Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Oxygenta Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Take a look at our analysis of 524636’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Oxygenta Pharmaceutical competitive advantages and company strategy can generally be found in its financial reports archived here.
How has Oxygenta Pharmaceutical performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 524636 is currently unprofitable.
Growing Profit Margin: 524636 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 524636 is unprofitable, but has reduced losses over the past 5 years at a rate of 39.5% per year.
Accelerating Growth: Unable to compare 524636's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 524636 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9%).
Return on Equity
High ROE: 524636's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Discover strong past performing companies
How is Oxygenta Pharmaceutical's financial position?
Financial Health Score0/6
Financial Health Score 0/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: 524636 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: 524636 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: 524636 has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: 524636's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if 524636 has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 524636 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is Oxygenta Pharmaceutical current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 524636's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 524636's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 524636's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 524636's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 524636 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sai Vankineni (71 yo)
Dr. Sai Sudhakar Vankineni serves as Managing Director and Chairman of the Board of S.S. Organics Limited since February 14, 2019. He served as Whole Time Director at S.S.Organics Limited since February 2...
Experienced Management: 524636's management team is considered experienced (2 years average tenure).
Experienced Board: 524636's board of directors are considered experienced (3.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 39.2%.
Oxygenta Pharmaceutical Limited's employee growth, exchange listings and data sources
- Name: Oxygenta Pharmaceutical Limited
- Ticker: 524636
- Exchange: BSE
- Founded: 1990
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹367.104m
- Shares outstanding: 14.20m
- Website: https://www.oxygentapharma.com
Number of Employees
- Oxygenta Pharmaceutical Limited
- Plot No: 43, Survey No: 55 to 58
- The Park View 1st Floor, Lumbini Avenue
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/04 00:00|
|End of Day Share Price||2022/07/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.